April 16 COVID-19 Quick Takes: ACIP to reconvene over J&J’s vaccine on April 23; plus Gilead, Lilly-AbCellera and Sputnik V

The CDC’s Advisory Committee on Immunization Practices will hold a virtual emergency meeting on April 23 to discuss the use of Johnson & Johnson’s vaccine. The committee may issue updated recommendations for the vaccine’s use after FDA recommended a pause due to reports of rare clotting events.

Gilead stops Phase III outpatient trial of Veklury
Gilead Sciences Inc. (NASDAQ:GILD) halted a Phase III trial of Veklury remdesivir to treat high-risk COVID-19 outpatients, citing challenges in patient enrollment and the shift in COVID-19 unmet needs for non-hospitalized patients toward convenient, at-home therapies. The company said the decision was not based on safety or efficacy concerns...